tiprankstipranks
Trending News
More News >
10x Genomics Inc (TXG)
NASDAQ:TXG
US Market

10x Genomics (TXG) Earnings Dates, Call Summary & Reports

Compare
1,061 Followers

Earnings Data

Report Date
Jul 31, 2025
TBA Not Confirmed
Period Ending
2025 (Q2)
Consensus EPS Forecast
-0.37
Last Year’s EPS
-0.32
Same Quarter Last Year
Moderate Buy
Based on 10 Analysts Ratings

Earnings Call Summary

Earnings Call Date:May 08, 2025
|
% Change Since: 9.15%
|
Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed outlook. While there were significant achievements in consumables growth, particularly in APAC, and promising product developments, these were overshadowed by declines in instrument revenue and substantial uncertainties in the U.S. research funding environment. The company's decision to withdraw full-year guidance reflects this uncertainty.
Company Guidance
During the first quarter of 2025, 10x Genomics reported total revenue of $155 million, including a $26 million gain from a settlement with Vizgen. Excluding this, revenue was $138 million, down 2% year-over-year. Consumables revenue grew by 5% to $115.4 million, with spatial consumables up 18%, while instrument revenue declined by 42% to $14.8 million. The company cited a challenging macro environment, especially within U.S. academic and government funding, as a significant factor affecting revenue, leading to the withdrawal of its full-year guidance. Approximately 40-50% of 10x Genomics' revenue is exposed to these funding sources. Gross profit for the quarter was $105.4 million with a margin of 68%, and operating expenses decreased to $144.8 million. The company ended the quarter with $427 million in cash and securities. Due to uncertainties, 10x Genomics implemented cost-cutting measures, including an 8% workforce reduction, anticipating a $50 million reduction in operating expenses for 2025. For the second quarter, revenue is expected to be between $138 million and $142 million. Despite the challenges, the company remains confident in the long-term growth potential of its products and market position.
Strong Consumables Revenue Growth
Total consumables revenue increased 5% year-over-year to $115.4 million, with spatial consumables revenue up 18%, driven by Xenium consumables.
Robust Demand in APAC
Revenue in the APAC region increased by 22%, with strong consumable sales offsetting declines in other areas.
Cost Reduction Measures
The company implemented cost-saving measures, including an 8% reduction in global workforce and significant reductions in non-headcount expenses, expected to reduce 2025 operating expenses by more than $50 million compared to 2024.
Positive Developments in Product Usage
Chromium reaction volumes showed robust year-over-year growth, and Xenium consumable revenue and volume continued to grow strongly.
Innovative Product Launches
Recent product launches, including GEM-X technology and Visium HD, continue to resonate with customers and advance the company's leadership in single-cell and spatial biology.

10x Genomics (TXG) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

TXG Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Jul 31, 2025
2025 (Q2)
-0.36 / -
-0.32
May 08, 2025
2025 (Q1)
-0.47 / -0.28
-0.544.00% (+0.22)
Feb 12, 2025
2024 (Q4)
-0.30 / -0.40
-0.412.44% (<+0.01)
Oct 29, 2024
2024 (Q3)
-0.33 / -0.30
-0.7962.03% (+0.49)
Aug 08, 2024
2024 (Q2)
-0.48 / -0.32
-0.5339.62% (+0.21)
Apr 30, 2024
2024 (Q1)
-0.50 / -0.50
-0.44-13.64% (-0.06)
Feb 15, 2024
2023 (Q4)
-0.35 / -0.41
-0.15-173.33% (-0.26)
Nov 02, 2023
2023 (Q3)
-0.46 / -0.79
-0.37-113.51% (-0.42)
Aug 03, 2023
2023 (Q2)
-0.40 / -0.53
-0.577.02% (+0.04)
May 03, 2023
2023 (Q1)
-0.37 / -0.44
-0.38-15.79% (-0.06)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

TXG Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 08, 2025
$8.63$8.77+1.62%
Feb 12, 2025
$12.00$11.94-0.50%
Oct 29, 2024
$15.79$16.49+4.43%
Aug 08, 2024
$19.55$20.43+4.50%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does 10x Genomics Inc (TXG) report earnings?
10x Genomics Inc (TXG) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
    What is 10x Genomics Inc (TXG) earnings time?
    10x Genomics Inc (TXG) earnings time is at Jul 31, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is TXG EPS forecast?
          TXG EPS forecast for the fiscal quarter 2025 (Q2) is -0.37.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis